Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Vermillion Board of Directors Nominates Paul R. Sohmer for Company Director

Published: Monday, October 15, 2012
Last Updated: Monday, October 15, 2012
Bookmark and Share
Nominee brings extensive management, governance and clinical diagnostics experience.

Vermillion, Inc. has announced that its board of directors has unanimously nominated Paul R. Sohmer, M.D. for election as a director at the upcoming annual meeting of stockholders.

Dr. Sohmer was recommended to serve on the board as an independent investor representative by a Vermillion stockholder with long-term holdings of approximately 5% of the company's outstanding common stock.

After consideration of Dr. Sohmer's background and qualifications, the board of directors determined he is an exceptionally qualified candidate.

"Paul's nomination is a perfect fit to our in vitro diagnostic business with his 27 years of experience in public and private growth companies focused on laboratory services, medical devices, and biotechnology," said James Burns, Vermillion's chairman.

Dr. Sohmer would bring a broad range of clinical diagnostics leadership experience to the board, having previously provided direction and oversight to numerous public and privately held companies engaged in the development, manufacture, marketing and sale of in vitro diagnostic reagents and instruments, as well as the delivery of hospital-based and esoteric reference laboratory services.

He also possesses a wealth of experience developing companies and increasing shareholder value via leveraging the capital markets, developing strategic alternatives, and leading merger and acquisition transactions.

Dr. Sohmer is currently president and CEO of Viracor-IBT Laboratories, Inc., a diagnostic and research laboratory specializing in allergy, immunology and infectious disease testing.

Prior to Viracor-IBT, he served as CEO of Orthocon, Inc., a developer, manufacturer and marketer of implantable medical products.

He also previously served as interim CEO of Cylex, Inc. and CEO of Pathway Diagnostics Ltd., during which time he also served on the board of RadPharm, Inc. and as chairman of Molecular Biometrics, Inc.

Earlier in his career he served as president and CEO of NASDAQ-listed Neuromedical Systems, Inc., until its acquisition by TriPath Imaging, Inc. a NASDAQ-listed cancer diagnostics company that developed and commercialized molecular diagnostic products for cervical, breast, ovarian and prostate cancers. He served TriPath as its chairman, president and CEO until it was purchased by Becton, Dickinson and Company, a leading global medical technology company.

Prior to Neuromedical Systems, he served as president and CEO of Genetrix, Inc., a genetic testing lab, until the company was acquired by Genzyme Corporation.

Before Genetrix, Dr. Sohmer was president and CEO of Pathology Institute, Inc., where he led the first commercial introduction of polymerase chain reaction for diagnosis of HIV and founded the Chiron Reference Laboratory.

Dr. Sohmer received his B.A. from Northwestern University and M.D. from the Chicago Medical School. He was named the Ernst and Young Carolinas Life Sciences Entrepreneur of the Year in 2005.

If elected, Dr. Sohmer would succeed current board member John F. Hamilton who has not been nominated for re-election at this meeting. "We thank John for his six years of exceptional service to the board," said Burns, "and we wish him continued success in his other endeavors."

Dr. Sohmer's election to the board, along with Vermillion's other nominee, would maintain the total number of directors on the board at seven, with six serving independently.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Clinical Study on the Relationship Between Imaging and OVA1®
New analysis explores interactions between clinical risk factors used in pre-surgical assessment.
Friday, March 21, 2014
Vermillion Reports Fourth Quarter and Full Year 2013 Results
Company will next pursue a national price for its OVA1 test in 2014.
Saturday, March 08, 2014
Vermillion to Present at the 26th Annual ROTH Conference
Company to present at the conference on March 11, 2014.
Thursday, March 06, 2014
Vermillion to Present at Leerink Global Healthcare Conference
Conference to be held at the Waldorf Astoria Hotel from February 12-13, 2014.
Tuesday, February 04, 2014
Vermillion Completes $17.6 Million Warrant Exercise
Proceeds from the warrant exercise will be used to increase test sales for OVA1.
Friday, December 20, 2013
Vermillion Reports Results of 2013 Annual Meeting
Company has approved the reappointment of Peter S. Roddy.
Friday, December 20, 2013
Vermillion Appoints SVP of Sales and Marketing and Chief Commercial Officer
Appointment of Marian E. Sacco as senior vice president of sales and marketing.
Friday, December 20, 2013
Vermillion Board of Directors Elects James T. LaFrance as Chairman
LaFrance has been appointed a member of Company’s board on December 12, 2013.
Monday, December 16, 2013
Vermillion Reports Third Quarter 2013 Results
Company reports Q3 2013 financial results and key developments.
Friday, November 15, 2013
American Journal of Obstetrics & Gynecology Publishes New Clinical Study of OVA1 Test
Significantly superior early-stage sensitivity shown versus CA125, modified ACOG guidelines or overall clinical assessment in premenopausal and postmenopausal women planning surgery.
Thursday, November 14, 2013
Vermillion Appoints Dr. Eric Varma to its Board of Directors
Dr. Varma is currently a partner at Oracle Investment Management.
Tuesday, September 17, 2013
Vermillion's OVA1 Receives New Statement by SGO
OVA1® has received new statement on clinical validation and medical use.
Tuesday, July 16, 2013
Vermillion Appoints President and Chief Executive Officer
Appointment of Thomas McLain effective March 18, 2013.
Thursday, July 04, 2013
Vermillion Appoints Bruce A. Huebner to Chairman of the Board
Shareholders to vote on approval of expanded stock incentive plan at upcoming annual meeting.
Friday, June 28, 2013
Vermillion Announces Closing of Equity Financing
Company to increase the number of directors of the Company from six to eight persons.
Thursday, May 16, 2013
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos